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A plant-incorportated protectant (PIP) is a pesticidal substance produced by a gene that 
has been inserted into a plant through transgenesis. EPA does not regulate the plant; in 
contrast to other regulatory agencies, we regulate the gene and the gene product.
As pointed out by Roger Beachy1, the definition of a pesticide has been around since 
947, when the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) was promul-
gated. In addition to language about destroying, repelling, and/or mitigating pests—“pests” 
are defined in the statute—it deals with plant regulators (not plant-growth regulators). 
Admittedly the category is broad, but then “pesticide” is difficult to define.
As far as I know, there is no inclination or intention to regulate plants expressing 
plant-growth regulators as pesticides, although, certainly, a policy statement to that effect 
might be helpful. Today, I am speaking specifically about plants that are disease- and/or 
pest-resistant.
Four statutes influence our authority to regulate PIPs (Figure ) of which I will focus on 
FIFRA, the main pesticide law, and the Federal Food Drug and Cosmetic Act (FFDCA) 
that we share with our colleagues at the Food and Drug Administration (FDA) regarding 
residues and tolerances.
FIFRA is unusual in terms of environmental statutes in that it considers benefits as 
well as risks, which is crucial with compounds that are inherently more toxic—typical 
nematicides, insecticides, etc., for example—but it can apply to PIPs in terms of envi-
ronmental safety or benefits and even economic safety and benefits. This does not apply 
to the Food Drug and Cosmetic Act.
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In terms of initiating the process of achieving deregulation, most typically applicants 
start with an experimental use permit (Figure ) to generate field data. It is particularly 
noteworthy that we do not generally regulate field trials at less than ten acres. Trials in 
excess of 0 acres are likely to be under an APHIS permit or notification process. If 
you’re clever about it, you can plant multiple 9-acre plots, depending on how you design 
them. It is about cumulative acreage, but addressing a specific question with each cumu-
lative 9.9 acres is acceptable and is not regulated by EPA as long as different pest-crop 
combinations are being evaluated in the plots of less than 0 acres. The point is to assist 
in the development of data characterizing the product and/or its chemistry that will be 
needed to ultimately achieve registration; it is not about producing seed for commercial 
purposes and the data generated cannot be used for promotional purposes. Of course, 
we need to know the origin of the transgene, its DNA sequence and the deduced amino 
acid sequence. Where Agrobacterium has been used, a plasmid map will be necessary. 
Also protein-expression levels are needed, typically determined at multiple stages in the 
plant’s growth as well as at multiple locations; this need results from oversight being 
defined through a law governing pesticides. The content of the pesticidal substance must 
be elucidated, which is true for all pesticides, whether it’s a liquid, a PIP, or a microbial 
compound. In addition, for purposes of insect-resistance management, it’s important to 
know the accumulation of the protein in a leaf at whatever stage. That’s particularly true 
with corn and cotton, and then, of course, an analytical method is required to detect the 
pesticidal substance, which is particularly important in trade.
Each event has a unique OECD2 identifier. Although we often look at things parochi-
ally, we must keep in mind that we are in a global economy. From a scientific standpoint, 
I understand why people often say, “We are familiar with Bt and it would be nice to just 
give it a pass from now on.” On the other hand, the Chinese, Koreans, Japanese, Austra-
lians, Brazilians and others may not agree with that. Putting a new product on the market 
Figure . EPA’s regulatory role.
2Organization for Economic Co-operation and Development.
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Figure . Experimental use permits.
Figure 3. Test substances.
needs to be done with some forethought prior to actual commercialization. Asynchrony 
in approval is an ongoing problem in international trade.
For the vast majority of our guideline studies, test substances are proteins, which are 
often generated in a yeast or E. coli-based fermentation system (Figure 3). It is then the 
responsibility of the applicant to demonstrate the equivalency of the protein produced in 
the model system to that produced in the plant. To assess human-health effects of PIPs, we 
run acute oral toxicity maximum hazard dose tests with animals. Admittedly unrealistic, 
they are run for short periods to show any potential toxicity. In some other countries, 
long-term feeding studies are the norm, to reveal chronic and sub chronic toxicity. We 
have this option available if the first-tier testing indicates that there might be an issue.
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Biochemical properties are assessed. If the protein is an enzyme or a toxin that binds 
something, that needs to be demonstrated. Importantly, we do a lot of hematology 
comparisons both for toxicity and for allergenicity, based on known toxins and known 
allergens. In addition, digestibility studies assess allergenicity as well. This raises another 
point: when choosing a gene for transgenic work, it’s best not to use a shellfish or a tree 
nut as the source, as it will raise red flags. That’s not necessarily an insurmountable issue, 
but it may be costly in time and money.
In terms of the environmental or eco-assessment, non-target effects are a chief concern, 
on vertebrates and invertebrates alike (Figure 4). Because we are dealing with pesticides, 
environmental fate is also an important issue. What happens to the pesticidal substance: 
does it bind to clay particles, does it dissipate or is it degraded? In addition, does the 
transgene in question move outside of the cropping system to an indigenous or even feral 
relative? If so, it is something that we would consider in terms of potential adverse effects 
on the environment. If a tolerance is in place—in other words if we approve the gene 
product for consumption in animal feed or human food—then crop-to-crop gene flow 
is not an issue for us, although it may be an issue for USDA-APHIS. We require that, 
once you get to the field-trial stage, tolerances should be in place.
Figure 4. Data required for ecological effects on non-target organisms.
Figure 4 also shows some instances where corners may be rounded off to save some 
money. Some are very likely to be applicable—avian oral toxicity for a protein, for 
example. Typically, the mammal test has already been done; for human food tolerance, 
that study suffices. Although all of these data requirements need to be fulfilled, not all 
of them need to be fulfilled with empirical data generation; some may be fulfilled with a 
waiver rationale. My attorneys warn me not to call it a “waiver” because that has specific 
legal connotations. But it’s a rationale. It may be a couple of paragraphs, a paper from 
35
the literature, or it may be based on an exposure argument showing that the PIP will not 
affect a target organism or other source of concern. There are ways to get around that. 
We have never had a PIP produced in a marine or estuarine environment, so we’ve never 
asked for a grass-shrimp test.
We don’t put a lot of weight in the 4-day poultry-feeding study, although other 
countries require it. Many of our registrants submit that, in which case we review it, but 
good data are needed from several other tests prior to getting to that stage.
Navigating EPA
EPA sets tolerances—maximum residue levels—for pesticides in or on food and feed 
products. A pesticide residue present in or on a food or feed product that is not covered 
by a tolerance, or an exemption from the requirement of a tolerance, means that the 
product is considered “adulterated” under the FFDCA and the FDA is responsible for 
enforcement. That is to be avoided.
Tolerances are set by considering data from acute oral toxicity tests, sequence compari-
sons to known toxins and allergens, in vitro digestibility and the source of the gene. We 
look at homology to known allergens; a good database is available at the University of 
Nebraska. It’s important to do such searches prior to progressing significantly, e.g. when 
building the constructs to verify that, by chance, the protein of interest doesn’t have a hit, 
i.e. a 35% or greater homology over an 80 amino acid stretch. If that is triggered then 
more testing will be called for.
Frequently, people call and take advantage of our guidance. It’s best to do so early on 
and not while in the midst of field trials only then to discover a problem.
As mentioned, most data requirements are designed for proteins as the test substance. 
If an RNA-interference approach is possible, it is likely to save time and money. People 
are spraying double-stranded RNAs, and bacterial vectors are being used to move RNAs 
into the environment. Although they’re not proteins, questions remain in terms of how 
bioinformatics may aid predictability of action toward non-target organisms. For example, 
do the RNAs quickly degrade after contact with the soil? A number of questions need data 
generation. Clearly, RNAi won’t solve everything, but where its use is possible, it should 
be considered. In addition, when inclusion of inert ingredients is needed, e.g. antibiotic 
and herbicide-tolerance markers, it makes sense to choose those that have been previously 
approved—glucuronidase, NPTII, EPSPS, PAD, etc.—again to save time and money.
Approval of green fluorescent protein has not yet been requested. The first such re-
quest will incur the cost of the required assessment. People have told me that a viable 
alternative approach will be to fuse NPTII and GUS. On the other hand, the tolerance 
for each of those individually may not apply to the fusion protein because truncation 
will change the sequence. Little things like that can cost more time and more money 
and, again, it’s wise to contact us early—which doesn’t cost anything—and hopefully, 
we can be of some help.
Now, in terms of the “barriers” that EPA’s Office of Pesticide Programs promotes, PRN 
-3 (Figure 5) denotes the third notice issued in 0 that provided guidance—in strong 
terms—for provision of data for applying for pesticide registration under FIFRA section 3 
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and FFDCA sections 408 and 409. The agency has a history of requiring particular format-
ting, to which there are advantages. In terms of record keeping, it lends efficiency when 
things are put together similarly and we have to find a piece of information pertaining 
to one of the thousands of products that we register. Initially it can be intimidating. We 
produce a registration manual that provides basic information (Figure 6). However, if 
you’ve never been through the process before, it can be helpful to employ an experienced 
consultant for guidance. We can provide a list of those who have worked with us, but we 
don’t recommend specific people. On the other hand, some people have gone through the 
process without a regulatory consultant. Ralph Scorza and colleagues at USDA-ARS wrote 
a chapter for a book3 that Alan McHughen and I edited in which he describes—without 
sugarcoating—his trials and tribulations in obtaining deregulation of pox-virus resistant 
plums. I think he’s correct, particularly in terms of his criticism of formatting require-
ments, which can be onerous. On the other hand, he did make it through the process, 
demonstrating that it is doable. Dr. Scorza is a good resource, particularly for academics 
who don’t have a regulatory staff.
Figure 5. PRN -3 formatting.
3Wozniak CA McHughen A (Eds) (0) Regulation of Agricultural Biotechnology: The United States and 
Canada. New York: Springer.
The Pesticide Registration Improvement Act—not a policy of the agency—is a statute 
passed by Congress. It was put together by stakeholders, NGOs, and industry and agency 
representatives in 004 (Figure 7). In its third iteration, it sets fee schedules. Companies 
with 500 or more employees have a particular fee schedule. For a university or USDA-
ARS scientist, waivers apply. For example a PI at Texas A&M will likely be eligible for a 
75 percent waiver in comparison with the company fee. If a large company applies for 
deregulation of a new active ingredient for first food use, the fee may be $400,000 to 
$500,000 upfront. Tables are available setting out fee schedules for different groups of 
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pesticides, These tables also provide firm timelines. These do not define when a registration 
will be granted, but rather when a decision will be made, on the assumption that a full 
and complete data package was submitted on day one. Some registrants have expressed 
approval of this approach because it removes some of the uncertainty; the previous queue 
system was inefficient. 
Figure 6. Where to begin.
Figure 7. Pesticide Registration Improvement Act (PRIA 3).
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Figure 8. Summary—navigating EPA.
Summary
Consultations can be very informal. It’s best if the applicant can visit EPA, but, otherwise, 
the initial consultation may be achieved by telephone, possibly a conference call, or email 
(Figure 8). Even a pre-submission meeting will be treated as confidential. At no cost, 
meeting minutes are generated, laying out what was discussed, what was agreed upon, 
what is left open, etc., which initiates the process. It is advisable to have consultations early 
on because they may lead to beneficial alterations, for example in terms of generation of 
less data or discovery of a waiver rationale. As mentioned, the formatting requirements 
are mandatory, and assistance of a consultant is recommended. However, absence of a 
consultant should be not considered as a deal breaker. Others have achieved deregulation, 
and EPA staff—regulatory specialists—are there to assist. 
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Figure 9. Sources of assistance.
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Several websites are available for guidance; they are continuously updated and improved 
(Figure 9). Kimberley Nesci or I may be contacted to set up a pre-submission meeting 
or to answer other questions.
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